Ganetespib (STA-9090)

Catalog No.S1159

Ganetespib (STA-9090) Chemical Structure

Molecular Weight(MW): 364.4

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Size Price Stock Quantity  
In DMSO USD 302 In stock
USD 270 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Breast cancer (MDA-MB-231), pancreatic cancer (PaTu2), lung cancer (A549), colon cancer HCT-116, and acute myeloid leukemia (SKM1) cell lines were incubated with increasing amounts of PU-H71 and STA-9090 as indicated. Western blot analysis with PRKD2, cleaved PARP, and cleaved caspase-9 antibodies is depicted.

    Cancer Res 2014 10.1158/0008-5472.CAN-14-1017. Ganetespib (STA-9090) purchased from Selleck.

    Western blot analysis of the expression of Brd4 and Hsp90 from whole-cell lysates of Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 at indicated concentrations for 24 h (B), and in Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 (200 nM) at indicated time points (C).

    Hum Mol Genet, 2015, 10.1093/hmg/ddv136. Ganetespib (STA-9090) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 NVPv[JdQSXCxcITvd4l{KEG|c3H5 MmjLN|AwQDBxMUWwM|I2OCCwTR?= NHq3S2UzPC92OD:3NkBp MljHbY5lfWOnczDkc5NmKGSncHXu[IFvfCCrbnT1Z5Rqd25ib3[gZZBweHSxc3nz NH;wb20zPTh6MkW1NC=>
MV411 NWrYUHVtSXCxcITvd4l{KEG|c3H5 NEK4e4E{OC96MD:xOVAwOjVyIH7N M4rD[lI1NzR6L{eyJIg> NWXkOJk2cW6mdXPld{Bld3OnIHTldIVv\GGwdDDpcoR2[3Srb36gc4Yh[XCxcITvd4l{ NGXLXIgzPTh6MkW1NC=>
MGC-803 MoG5R4VtdCCYaXHibYxqfHliQYPzZZk> NIrtUIExNjFvMUCwNEBvVQ>? Mn\MO|IhcA>? NXLIPG94cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M4Xh[FI2PTlyOEC1
SGC-7901 Mn21R4VtdCCYaXHibYxqfHliQYPzZZk> M3yzPVAvOS1zMECwJI5O M1H4eFczKGh? MVrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NUTYWYlWOjV3OUC4NFU>
MKN-28 Mn3FR4VtdCCYaXHibYxqfHliQYPzZZk> M{LWUVAvOS1zMECwJI5O MmrUO|IhcA>? NIXWOo9qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MYOyOVU6ODhyNR?=
MGC-803 MYDGeY5kfGmxbjDBd5NigQ>? M2noVlAvOS1zMECwJI5O NVG2XIhYOjRiaB?= M33nfIlv\HWlZYOgS|IwVSClZXzsMYN6[2ynIHHydoV{fA>? M1fjPFI2PTlyOEC1
HCT-116 NFT3R4VHfW6ldHnvckBCe3OjeR?= NHr3TFY2OG6P M4HzVVI1KGh? MV\EUXNQ NEPMToNqdmS3Y3XkJGcxN0dzIHHydoV{fA>? NY\pUYVNOjV{MUC3PVQ>
HT-29 MmD1SpVv[3Srb36gRZN{[Xl? NEL4S4M2OG6P NFXmdoIzPCCq MnL4SG1UVw>? NWDXUnY5cW6mdXPl[EBIOC:JMTDhdpJme3R? MY[yOVIyODd7NB?=
SCC25 NGHVc4REgXSxeHnjbZR6KEG|c3H5 MkfZNVAwPTBibl2= MVWyOEBp NHu0b2Nl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> M3nxb|I2OjB3NEOw
FUDA NEn0OWNEgXSxeHnjbZR6KEG|c3H5 NXXpd2pNOTBxNUCgcm0> M4Dl[lI1KGh? NFPORlll\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> M{PxdlI2OjB3NEOw
Detroit562 MWDDfZRwgGmlaYT5JGF{e2G7 MX:xNE82OCCwTR?= NGr5XXAzPCCq MWTk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= M2\vSlI2OjB3NEOw
CAL27 MYrDfZRwgGmlaYT5JGF{e2G7 MnfhNVAwPTBibl2= MUCyOEBp MYnk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= Mm\4NlUzODV2M{C=
DSH1 M3T1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTZibl2= M1Xx[lI1Pzh2OEO5
SW-1710 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;TTWJKSzVyPU[gcm0> MYCyOFc5PDh|OR?=
T24 NH3OOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;LdZZzUUN3ME23JI5O NX3VVplvOjR5OES4N|k>
RT112 NXLOXlhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITLe5pKSzVyPUmgcm0> MWOyOFc5PDh|OR?=
639-V MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFyIH7N MmnvNlQ4QDR6M{m=
SCaBER M4Pqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy4VGtKSzVyPUGwJI5O NV\q[VRIOjR5OES4N|k>
BFTC NVrjSYNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\4XWlEPTB;MUegcm0> M3XDO|I1Pzh2OEO5
J82 NFW2[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvKTWM2OD1zODDuUS=> M4rpNlI1Pzh2OEO5
HT-1376 MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzQeWp7UUN3ME2yNUBvVQ>? NUD2O4JbOjR5OES4N|k>
647-V NIDNOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESw[GpKSzVyPUK3JI5O M37lOlI1Pzh2OEO5
UM-UC3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3pc|hSUUN3ME2zN{BvVQ>? NEnyO2szPDd6NEizPS=>
LB831-BLC MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfq[I9jUUN3ME2zOEBvVQ>? MX6yOFc5PDh|OR?=
KU-19-19 NE\4fmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfhSW41UUN3ME2zOkBvVQ>? MUeyOFc5PDh|OR?=
35612 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXmfXU1UUN3ME2zPEBvVQ>? MViyOFc5PDh|OR?=
5637 NG\BSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DOPWlEPTB;NESgcm0> NWL3OodyOjR5OES4N|k>
HT-1197 M2rjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnpPWh7UUN3ME21N{BvVQ>? MV[yOFc5PDh|OR?=
MGH-U3 M2D2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLFWVNEUUN3ME21N{BvVQ>? NGfTZVYzPDd6NEizPS=>
TCCSUP NHTKbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF2MjDuUS=> Mn;NNlQ4QDR6M{m=
RT4 NITjXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLjSWxGUUN3ME2xO|M{KG6P NXe4U2l{OjR5OES4N|k>
SW780 NVjDc|NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXDTWM2OD1|NEWxJI5O NWn2WHV1OjR5OES4N|k>
RKO MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTRibl2= M3jKb|I1Pjh{N{S3
LS-411 N M33wTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfUbFVTUUN3ME21JI5O NGrKbG8zPDZ6Mke0Oy=>
SW620 NX\CVnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvXbHFKSzVyPUigcm0> NH3RNY0zPDZ6Mke0Oy=>
HCT-15 MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[4UZVKSzVyPUigcm0> NGfucWszPDZ6Mke0Oy=>
HuTu-80 NYnRW4FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHuTWM2OD1zMzDuUS=> NYrKR5l[OjR4OEK3OFc>
HCT 116 NU\re2U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXLUWVTUUN3ME2xOEBvVQ>? M1uxclI1Pjh{N{S3
COLO-205 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i2WmlEPTB;MUSgcm0> NF\QSpMzPDZ6Mke0Oy=>
NCI-H747 M2LSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF5IH7N NFTGbWgzPDZ6Mke0Oy=>
COLO-678 NUK5OlhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DC[GlEPTB;MkGgcm0> NGjodFkzPDZ6Mke0Oy=>
LoVo NVX5[2V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ{IH7N NHvnVGQzPDZ6Mke0Oy=>
LS-1034 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y3NWlEPTB;M{Ggcm0> NX7IN5Z4OjR4OEK3OFc>
SNU-C2B MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi5TWM2OD12NTDuUS=> Mn[3NlQ3QDJ5NEe=
LS-123 NHPWOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nIbmlEPTB;N{Ogcm0> MkjPNlQ3QDJ5NEe=
SK-CO-1 NVnPNmF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrSUZNrUUN3ME24NUBvVQ>? NF6y[3YzPDZ6Mke0Oy=>
HCC2998 NEXUOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF{ODDuUS=> NELWcVYzPDZ6Mke0Oy=>
MDA-MB-231 M2H3TWZ2dmO2aX;uJGF{e2G7 NH3Ffm4yODBibl2= M2G1S|MxKG2rbh?= NHH6e5pqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gTGlHNTIQsR?= MoXyNlQzPDh{NkW=
MDA-MB-435 NFrjXllHfW6ldHnvckBCe3OjeR?= NWj5dY51OTByIH7N MX6zNEBucW5? MnjybY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIFjJSk0y|rF? MUKyOFI1QDJ4NR?=
BT-20  MYfGeY5kfGmxbjDBd5NigQ>? NXvoS4x{OTByL{K1NEBvVQ>? M2LOU|I1KGh? NWn3Z4ptemW|dXz0[YQhcW5iYTDkc5NmNWSncHXu[IVvfCCmZYP0ZYJqdGm8YYTpc44hd2ZiRVfGVkwhUUeILVnSMEBOTVRuIHHu[EBEWkGI MnvqNlQyPzN3NEG=
MDA-MB-231 NVjiVIV6TnWwY4Tpc44hSXO|YYm= MX:xNFAhdk1? NXXMTHBZOjRiaB?= MlfBbY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCjbnSgbY53[XOrdnWgZ4Fx[WOrdIpCpC=> NXKwNYVqOjRzN{O1OFE>
H82 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1njOGlEPTB;M{CuNlchdk1? NUjhZYFROjRzNk[1NFU>
GLC4 M{jqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33qSWlEPTB;MkCuOFchdk1? M1;SZVI1OTZ4NUC1
H69 M1PwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTh|LkO2JI5O NEf3fG0zPDF4NkWwOS=>
H128 M2n2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7UTYJ7UUN3ME22PU42PSCwTR?= MkfaNlQyPjZ3MEW=
H146 NHrSZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJ6LkWxJI5O NY[2RoQxOjRzNk[1NFU>
H187 NFXyUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXSTWM2OD1{ND65PUBvVQ>? NEiySnUzPDF4NkWwOS=>
H526 M4\zcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DHWGlEPTB;MkGuOlQhdk1? NYXod21EOjRzNk[1NFU>
N592 NWnvWlVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjQVHJKSzVyPUG0MlEzKG6P MmfqNlQyPjZ3MEW=
H620 NUjTXolFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWxV3p2UUN3ME2zNk43PyCwTR?= NInrcpczPDF4NkWwOS=>
H792 M1PsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLtTWM2OD12NT6wO{BvVQ>? MVOyOFE3PjVyNR?=
H1173 NEjNdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3KybmlEPTB;MUKuOlIhdk1? MX[yOFE3PjVyNR?=
AC3 NXriVmZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULNcXpvUUN3ME2yOU46KG6P MX6yOFE3PjVyNR?=
H82 NIjrPHlHfW6ldHnvckBCe3OjeR?= M37NdVMxKG6P NYPsdHRKPzJiaB?= MYfpcoR2[2W|IIDldpNqe3SnboSgS|IwVSCyaHHz[UBienKnc4S= M{TPXlI1OTZ4NUC1
GLC4 NIX3SWVHfW6ldHnvckBCe3OjeR?= NVu2[Jh2OzBibl2= NEPxOHY4OiCq NYjwWGRCcW6mdXPld{Bx\XK|aYP0[Y51KEd{L12gdIhie2ViYYLy[ZN1 MWSyOFE3PjVyNR?=
H146  MkfLSpVv[3Srb36gRZN{[Xl? M{HrR|MxKG6P NVq1PHNsPzJiaB?= NICwWoZqdmS3Y3XzJJBmenOrc4TlcpQhTzJxTTDwbIF{\SCjcoLld5Q> NWLrUFV2OjRzNk[1NFU>
OVCAR-5 NVrsW|htS2WubDDWbYFjcWyrdImgRZN{[Xl? MViwMVExODBibl2= NGf1[po4OiCq M4XScYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MV2yN|kxODF|Nh?=
OVCAR-8 MmjaR4VtdCCYaXHibYxqfHliQYPzZZk> M2PsTVAuOTByMDDuUS=> NXfWNI86PzJiaB?= NVvseIxFcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MmXINlM6ODBzM{[=
A1847 MoC0R4VtdCCYaXHibYxqfHliQYPzZZk> NF;6WmgxNTFyMECgcm0> MVm3NkBp M2DnZolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MWGyN|kxODF|Nh?=
SKOV-3 NWT0SopuS2WubDDWbYFjcWyrdImgRZN{[Xl? NVzDfVNPOC1zMECwJI5O Mmq3O|IhcA>? M2XnWolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MX2yN|kxODF|Nh?=
OVCAR-5 MlTGRZBweHSxc3nzJGF{e2G7 MXOxNE0yODBibl2= NYjk[2h4OjRxNEivO|IhcA>? M2TH[Ylv\HWlZYOgZZBweHSxc3nzJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62bIm= M3jWRlI{QTByMUO2
OVCAR-8 MWXBdI9xfG:|aYOgRZN{[Xl? MnHXNVAuOTByIH7N M4K3bVI1NzR6L{eyJIg> Mmq3bY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?= M1r1flI{QTByMUO2
A1847 Ml3kRZBweHSxc3nzJGF{e2G7 NWm2cZFxOTBvMUCwJI5O M2DscVI1NzR6L{eyJIg> MoTwbY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?= NGTEUHYzOzlyMEGzOi=>
H2228 Ml[zR4VtdCCYaXHibYxqfHliQYPzZZk> MoP6NE0yODByIH7N MVu3NkBp M2jVPGlEPTB;MUOgcm0> M4mzO|I{PTN|Mk[1
H3122 MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnHONE0yODByIH7N NF24eGw4OiCq MYnJR|UxRTFyIH7N NXL3ZppQOjN3M{OyOlU>
K008 NHrHPGhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVrKcWl3UUN3ME22NEBvVQ>? NX\q[HRnOjN2MUi1NlM>
K028 NI\XfoJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGm1SlNKSzVyPUi0JI5O Ml;nNlM1OTh3MkO=
K029 NXXyZoJIS2WubDDWbYFjcWyrdImgRZN{[Xl? NG[ydJNKSzVyPUS2JI5O MW[yN|QyQDV{Mx?=
M23 M4ThS2NmdGxiVnnhZoltcXS7IFHzd4F6 MYnJR|UxRTN5LkWgcm0> MkW0NlM1OTh3MkO=
K033 MnT3R4VtdCCYaXHibYxqfHliQYPzZZk> MWDJR|UxRTd3LkWgcm0> M{\rclI{PDF6NUKz
K008 MXzGeY5kfGmxbjDBd5NigQ>? MUGyOVAhdk1? NVPnXmx5OjRiaB?= M3fBU4lv\HWlZYOgS|Ih[XK{ZYP0 MXmyN|QyQDV{Mx?=
K028 M3nBPGZ2dmO2aX;uJGF{e2G7 NF70fWkzPTBibl2= NFTKZ3EzPCCq Ml36bY5lfWOnczDHNkBienKnc4S= MnrVNlM1OTh3MkO=
K029 MknuSpVv[3Srb36gRZN{[Xl? MmLaNlUxKG6P NXTWdHd[OjRiaB?= MYXpcoR2[2W|IFexJIFzemW|dB?= MWGyN|QyQDV{Mx?=
M23 M3vHXGZ2dmO2aX;uJGF{e2G7 M4DBfFI2OCCwTR?= M1XqW|I1KGh? MkjYbY5lfWOnczDHNUBidmRiR{KvUUBienKnc4S= NVG5OHNQOjN2MUi1NlM>
K033 Mmq1SpVv[3Srb36gRZN{[Xl? NXGyU4NJOjVyIH7N MmjxNlQhcA>? NXKxcmpEcW6mdXPld{BiKG2xZHXzeEBqdmO{ZXHz[UBqdiCJMTDwc5B2dGG2aX;u NXzSXVFjOjN2MUi1NlM>
K008 NFPXUIVCeG:ydH;zbZMhSXO|YYm= NHmy[3EyODBibl2= NIHqRpY4OiCq MWTzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ MkW1NlM1OTh3MkO=
K028 NH7uVlFCeG:ydH;zbZMhSXO|YYm= NGDEdoUyODBibl2= NVPqdlY5PzJiaB?= MmTad4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? MnS2NlM1OTh3MkO=
K029 MknpRZBweHSxc3nzJGF{e2G7 NFfkO5oyODBibl2= M33FOlczKGh? Mn;pd4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? NGLQSZUzOzRzOEWyNy=>
M23 M33KNWFxd3C2b4Ppd{BCe3OjeR?= MWixNFAhdk1? MkLNO|IhcA>? M1jhU5Nq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN? NFS0SY8zOzRzOEWyNy=>
K033 MYjBdI9xfG:|aYOgRZN{[Xl? NUXKO3c3OTByIH7N MlHUO|IhcA>? NH3JZY1{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| NUTiVYFjOjN2MUi1NlM>
RD NEnOe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;odJJPUUN3ME24JI5O M{XwRVI{OzB|N{Sx
Rh41 NG\qPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTXTWM2OD1zMD60JI5O NF;qRXUzOzNyM{e0NS=>
Rh18 NGLoVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\GWmlEPTB;Nj6yJI5O NWP6VW9VOjN|MEO3OFE>
Rh30 NX63PZY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfsSpBKSzVyPUWuOkBvVQ>? MnrjNlM{ODN5NEG=
BT-12 NF;3TJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz4O2g3UUN3ME2xOE4{KG6P M3LhRlI{OzB|N{Sx
CHLA-266 NWTwSJFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[yUoNSUUN3ME2yO{4yKG6P MkL0NlM{ODN5NEG=
TC-71 M1fPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwNTDuUS=> M3m1WlI{OzB|N{Sx
CHLA-9 M2jMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTRwNjDuUS=> NVvWUXNxOjN|MEO3OFE>
CHLA-10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn76TWM2OD13Lkegcm0> NWX3UFhCOjN|MEO3OFE>
CHLA-258 MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7OTnQ{UUN3ME22MlQhdk1? Mo\sNlM{ODN5NEG=
SJ-GBM2 NIrXV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF{Lkmgcm0> MYiyN|MxOzd2MR?=
NB-1643 M4K1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjkdYNmUUN3ME23MlQhdk1? MUiyN|MxOzd2MR?=
NB-EBc1 NVL3eoFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTLTWM2OD1zNj64JI5O MYGyN|MxOzd2MR?=
CHLA-90 NUC2W|kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\ZTWM2OD1{Mj6zJI5O MnvhNlM{ODN5NEG=
CHLA-136 NGjW[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPWWZZKSzVyPUKzMlIhdk1? MnjaNlM{ODN5NEG=
NALM-6 NEn1NolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;TXZluUUN3ME2xNU44KG6P MX6yN|MxOzd2MR?=
COG-LL-317 NEPOZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULhZ2FwUUN3ME20MlQhdk1? NGnqPJAzOzNyM{e0NS=>
RS4;11 M1;kVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjxTWM2OD1zMz61JI5O MoPjNlM{ODN5NEG=
MOLT-4 M2fYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjLRWh5UUN3ME2xNE43KG6P NX7rcowxOjN|MEO3OFE>
CCRF-CEM (1) NFv3VlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLFZpc6UUN3ME2xNk42KG6P M2XIOVI{OzB|N{Sx
CCRF-CEM (2) NHzhR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfobI96UUN3ME23MlIhdk1? NFvYTVIzOzNyM{e0NS=>
Kasumi-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXE[mpMUUN3ME21Mlghdk1? M3z5d|I{OzB|N{Sx
Karpas-299 M{CxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\vd25KSzVyPUmuOkBvVQ>? NEnFb2QzOzNyM{e0NS=>
Ramos-RA1 NYDpPZluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHYWY9yUUN3ME23MlQhdk1? MnjRNlM{ODN5NEG=
LNCaP NIe0eppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnoS41[UUN3ME24JI5O NY\DPZQxOjNzNUKwNFQ>
VCaP MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fV[GlEPTB;NzDuUS=> M2jrW|I{OTV{MEC0
H1355 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnziTWM2OD13IH7N MV[yN|AyOjJ2OB?=
H157 MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DwRWlEPTB;NzDuUS=> M3nrNFI{ODF{MkS4
H460 MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDMbGVKSzVyPUigcm0> NYCxe5BMOjNyMUKyOFg>
IA-LM M4fLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\nTWM2OD1zMDDuUS=> NUTId5g6OjNyMUKyOFg>
HOP-62 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFzIH7N NV\qRWpsOjNyMUKyOFg>
H23 NHnJTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFzIH7N NIPz[HozOzBzMkK0PC=>
H2030 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzRTWM2OD1zMjDuUS=> NW\JZo1nOjNyMUKyOFg>
H441 M4\iRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEftPW9KSzVyPUG0JI5O NYfqNYlCOjNyMUKyOFg>
H2212 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHIcXRKSzVyPUG3JI5O MX2yN|AyOjJ2OB?=
SK-LU-1 NUfhe2JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLXTWM2OD1zODDuUS=> Mk[0NlMxOTJ{NEi=
H2009 NIHCTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXLTWM2OD1zOTDuUS=> MWeyN|AyOjJ2OB?=
H1792 NXuyOFBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6yfoJFUUN3ME2yNEBvVQ>? NGD4RngzOzBzMkK0PC=>
COR-L23 NUj6WYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ{IH7N M4XTTFI{ODF{MkS4
H727 NYTUTnhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvQeHBZUUN3ME2yPEBvVQ>? Moe0NlMxOTJ{NEi=
H1734 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly5TWM2OD1{ODDuUS=> M2jMbVI{ODF{MkS4
H358 NHPFW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrucYRKSzVyPUK5JI5O MkjENlMxOTJ{NEi=
A549 NI\LdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fvfGlEPTB;NEOgcm0> NH3ZU2YzOzBzMkK0PC=>
H2122 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTV|IH7N M3rz[|I{ODF{MkS4
Calu-1 M13UdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn5TWM2OD13ODDuUS=> NGjuN48zOzBzMkK0PC=>
Calu-6 NXfVe5F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTZ2IH7N NXG2ZmgzOjNyMUKyOFg>
NCI-H1975 M2XleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrzeYU1QCCq NE\wUIVKSzVyPUG2JI5O MlG5NlIyPDR4NkW=
NCI-H1975 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS3NkBp MXHJR|UxRThibl2= Mk[zNlIyPDR4NkW=

... Click to View More Cell Line Experimental Data

In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OSA cells
  • Concentrations: 0.001-1μM
  • Incubation Time: 5 days
  • Method: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female severe combined immune-deficient (SCID) mice
  • Formulation: In DMSO and diluted 1:10 with 20% Cremophor RH 40
  • Dosages: 25 mg/kg/day for 3 days
  • Administration: Tail vein injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 40 mg/mL (109.76 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02192541 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 9, 2014 Phase 1
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 --
NCT02389751 Active, not recruiting Esophageal Cancer M.D. Anderson Cancer Center|Synta Pharmaceuticals Corp. April 2015 Phase 1
NCT02334319 Terminated Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Oral Cavity Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma|Stage II Hypopharyngeal Squamous Cell Carcinoma|Stage II Laryngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma Emory University|Synta Pharmaceuticals Corp. December 2014 Phase 1
NCT02261805 Terminated Cancer|Small Cell Lung Cancer Georgetown University|Synta Pharmaceuticals Corp. October 2014 Phase 1|Phase 2
NCT02272478 Recruiting Acute Myeloid Leukaemia|Myelodysplastic Syndrome Cardiff University|Cancer Research UK October 2014 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID